Powder: -20°C for 3 years | In solvent: -80°C for 1 year
RN-18是 HIV-1 病毒感染因子的一种拮抗剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 285 | 现货 | ||
5 mg | ¥ 668 | 现货 | ||
10 mg | ¥ 1,070 | 现货 | ||
25 mg | ¥ 2,150 | 现货 | ||
50 mg | ¥ 3,230 | 现货 | ||
100 mg | ¥ 4,970 | 现货 | ||
500 mg | ¥ 9,870 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 738 | 现货 |
产品描述 | RN-18 is an inhibitor of HIV-1 viral infectivity factor (IC50: 6 μM in nonpermissive H9 cells). |
靶点活性 | Non-permissive H9 cells:6 μM (IC50) |
体外活性 | RN-18 displays the greater potency (IC50=4.5 μM in CEM cells) and specificity (IC50>100 μM in MT4 cells) among the two compounds. RN-18 and RN-19 show effective antiviral activity in the nonpermissive H9 and CEM cells but not in MT4 or CEM-SS cells, confirming that the antiviral activity was Vif specific. RN-18 also exhibits antiviral activity in CEM-SS modified to stably express A3G but does not exhibit antiviral activity in the parental CEM-SS cell line. RN-18 increases cellular A3G levels in a Vif-dependent manner and increases A3G incorporation into virions without inhibiting general proteasome-mediated protein degradation. RN-18 enhances Vif degradation only in the presence of A3G, reduces viral infectivity by increasing A3G incorporation into virions, and enhances cytidine deamination of the viral genome. Reverse transcriptase activity in the nonpermissive H9 and CEM cells decreases substantially and in a dose-dependent manner in the presence of the inhibitor RN-18. RN-18 antagonizes the Vif function and inhibits HIV-1 replication only in the presence of A3G [1][2]. |
分子量 | 380.42 |
分子式 | C20H16N2O4S |
CAS No. | 431980-38-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 97 mg/mL (254.98 mM), Sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.6287 mL | 13.1434 mL | 26.2867 mL | 65.7168 mL |
5 mM | 0.5257 mL | 2.6287 mL | 5.2573 mL | 13.1434 mL | |
10 mM | 0.2629 mL | 1.3143 mL | 2.6287 mL | 6.5717 mL | |
20 mM | 0.1314 mL | 0.6572 mL | 1.3143 mL | 3.2858 mL | |
50 mM | 0.0526 mL | 0.2629 mL | 0.5257 mL | 1.3143 mL | |
100 mM | 0.0263 mL | 0.1314 mL | 0.2629 mL | 0.6572 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
RN-18 431980-38-0 Microbiology/Virology Proteases/Proteasome HIV Protease inhibit Inhibitor Human immunodeficiency virus RN18 HIV RN 18 inhibitor